|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ticagrelor#Patient Counseling Information]] |
| {{Ticagrelor}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
| | |
| ==Patient Counseling Information==
| |
| | |
| See FDA-approved patient labeling (Medication Guide)
| |
| | |
| ===Benefits and Risks===
| |
| | |
| * Tell patients to take BRILINTA exactly as prescribed.
| |
| * Inform patients not to discontinue BRILINTA without discussing it with the prescribing physician.
| |
| * Tell patients daily doses of aspirin should not exceed 100 mg and to avoid taking any other medications that contain aspirin.
| |
| * Tell patients to read the Medication Guide.
| |
| | |
| ===Bleeding===
| |
| | |
| Inform patients that they:
| |
| | |
| * Will bleed and bruise more easily
| |
| * Will take longer than usual to stop bleeding
| |
| * Should report any unanticipated, prolonged or excessive bleeding, or blood in their stool or [[urine]].
| |
| | |
| ===Other Signs and Symptoms Requiring Medical Attention===
| |
| | |
| * Inform patients that BRILINTA can cause shortness of breath.
| |
| * Tell them to contact their doctor if they experience unexpected shortness of breath, especially if severe.
| |
| | |
| ===Invasive Procedures===
| |
| | |
| Instruct patients to:
| |
| | |
| * Inform physicians and dentists that they are taking BRILINTA before any surgery or dental procedure.
| |
| * Tell the doctor performing any surgery or dental procedure to talk to the prescribing physician before stopping BRILINTA.
| |
| | |
| ===Concomitant Medications===
| |
| | |
| * Tell patients to list all prescription medications, over-the-counter medications or dietary supplements they are taking or plan to take so the physician knows about other treatments that may affect bleeding risk (e.g. warfarin, heparin). <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = | date = | accessdate = 26 February 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = |date = | accessdate = 26 February 2014 }}</ref>
| |
| {{Reflist|2}}
| |
| | |
| {{Antithrombotics}}
| |
| | |
| [[Category:ADP receptor inhibitors]]
| |
| [[Category:Triazolopyrimidines]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Alcohols]]
| |
| [[Category:AstraZeneca]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |